Man Group
MGX icon

Man Group’s Metagenomi Therapeutics MGX Stock Holding History

Man Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
109,130
+30,494
+39% +$40.8K ﹤0.01% 2294
2026
Q1 		$105K Buy
78,636
+22,139
+39% +$34.4K ﹤0.01% 2347
2025
Q4 		$91.5K Buy
56,497
+3,609
+7% +$7.81K ﹤0.01% 2206
2025
Q3 		$125K Buy
+52,888
New +$107K ﹤0.01% 2144

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Man Group's MGX Position: Q2 2026 in Review

Man Group increased its Metagenomi Therapeutics (MGX) stake by 39% in Q2 2026, buying an estimated $40.8K and bringing the position to 109,130 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Man Group first reported a position in MGX in Q3 2025 and has held it in 4 quarters since. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Man Group held 109,130 shares of Metagenomi Therapeutics worth $130K as of Q2 2026.
  • Man Group bought 30,494 Metagenomi Therapeutics shares in Q2 2026, an estimated $40.8K.
  • Metagenomi Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2294 holding.
  • Man Group first reported a position in Metagenomi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.